{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T22:03:19Z","timestamp":1764194599891},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Financial disclosure: This work was supported by grant the Zhejiang Public Welfare Foundation","award":["GF18H180002"],"award-info":[{"award-number":["GF18H180002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2021,12]]},"abstract":"Abstract<\/jats:title>\n Background<\/jats:title>\n It has been reported the prognostic value of MTV in predicting the disease prognosis of peripheral T-cell lymphoma (PTCL) through pre-treatment PET\/CT imaging. However, these are limited data on pretreatment evaluation and prognosis assessments of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). This study aimed to determine the prognostic values of pre-treatment and mid-treatment total metabolic tumor volume (MTV), total lesion glycolysis (TLG), and Deauville 5-Point Scale (D-5PS) in accessing the prognosis of PTCL-NOS.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n A retrospective analysis was conducted in 31 patients with pathologically diagnosed PTCL-NOS. These patients have undergone positron emission PET\/CT scanning before and during chemotherapy. Follow-ups were also done to investigate the 2-year progression-free survival (PFS) and Overall Survival (OS) of these patients. During $${}^{18}$$<\/jats:tex-math>\n \n \n 18<\/mml:mn>\n <\/mml:msup>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>F-fluorodeoxyglucose ($${}^{18}$$<\/jats:tex-math>\n \n \n 18<\/mml:mn>\n <\/mml:msup>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>F-FDG) PET\/CT scans, the MTV and TLG were recorded. Meanwhile, $$\\bigtriangleup$$<\/jats:tex-math>\n \u25b3<\/mml:mo>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>MTV and $$\\bigtriangleup$$<\/jats:tex-math>\n \u25b3<\/mml:mo>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>TLG were calculated. Furthermore, the receiver operating characteristic (ROC) curve was employed to classify and to define the threshold values. On the other hand, the mid-chemotherapy assessment and staging of these 31 patients were done by utilizing D-5PS. Subsequently, based on the D-5PS scores obtained, these patients were grouped into two categories: a group of patients with a score of <4 and another group with $$\\ge$$<\/jats:tex-math>\n \u2265<\/mml:mo>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>4 points. For these two groups of patients, the survival analysis was done by Kaplan\u2013Meier analysis and a multivariate COX regression model. Moreover, Pearson\u2019s chi-square test ($$\\chi ^{2}$$<\/jats:tex-math>\n \n \u03c7<\/mml:mi>\n 2<\/mml:mn>\n <\/mml:msup>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula> test) and Spearman rank correlation coefficient were used to comparing the collected data, respectively.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n During the 2-year follow-up period, 15 out of the 31 patients experienced disease progression. The optimal threshold values for both baseline MTV and TLG were 158.16\u00a0cm$$^{3}$$<\/jats:tex-math>\n \n \n 3<\/mml:mn>\n <\/mml:msup>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula> and 677.40.Additionally, the difference in 2-year PFS between the progressive and non-progressive groups was statistically significant ($$\\chi ^{2}=8.193$$<\/jats:tex-math>\n \n \n \u03c7<\/mml:mi>\n 2<\/mml:mn>\n <\/mml:msup>\n =<\/mml:mo>\n 8.193<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>, $$P=0.004<0.05$$<\/jats:tex-math>\n \n P<\/mml:mi>\n =<\/mml:mo>\n 0.004<\/mml:mn>\n <<\/mml:mo>\n 0.05<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>; $$\\chi ^{2}=8.872$$<\/jats:tex-math>\n \n \n \u03c7<\/mml:mi>\n 2<\/mml:mn>\n <\/mml:msup>\n =<\/mml:mo>\n 8.872<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>, $$P=0.003<0.05$$<\/jats:tex-math>\n \n P<\/mml:mi>\n =<\/mml:mo>\n 0.003<\/mml:mn>\n <<\/mml:mo>\n 0.05<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>), significant between-group difference was detected for MTV and for TLG ($$\\chi ^{2}=6.494$$<\/jats:tex-math>\n \n \n \u03c7<\/mml:mi>\n 2<\/mml:mn>\n <\/mml:msup>\n =<\/mml:mo>\n 6.494<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>, $$P=0.011<0.05$$<\/jats:tex-math>\n \n P<\/mml:mi>\n =<\/mml:mo>\n 0.011<\/mml:mn>\n <<\/mml:mo>\n 0.05<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>; $$\\chi ^{2}=4.687$$<\/jats:tex-math>\n \n \n \u03c7<\/mml:mi>\n 2<\/mml:mn>\n <\/mml:msup>\n =<\/mml:mo>\n 4.687<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>, $$P=0.03<0.05$$<\/jats:tex-math>\n \n P<\/mml:mi>\n =<\/mml:mo>\n 0.03<\/mml:mn>\n <<\/mml:mo>\n 0.05<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>). On the other hand, when these patients were classified into two groups according to the mid-chemotherapy Deauville score of <4 and $$\\ge$$<\/jats:tex-math>\n \u2265<\/mml:mo>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>4, the statistical difference of 2-year PFS between these two groups was significant, too ($$\\chi ^{2}=14.966$$<\/jats:tex-math>\n \n \n \u03c7<\/mml:mi>\n 2<\/mml:mn>\n <\/mml:msup>\n =<\/mml:mo>\n 14.966<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>, $$P=0.001<0.05$$<\/jats:tex-math>\n \n P<\/mml:mi>\n =<\/mml:mo>\n 0.001<\/mml:mn>\n <<\/mml:mo>\n 0.05<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>),but there is no significant between-group difference in OS ($$\\chi ^{2}=3.337$$<\/jats:tex-math>\n \n \n \u03c7<\/mml:mi>\n 2<\/mml:mn>\n <\/mml:msup>\n =<\/mml:mo>\n 3.337<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>, $$P=0.068<0.05$$<\/jats:tex-math>\n \n P<\/mml:mi>\n =<\/mml:mo>\n 0.068<\/mml:mn>\n <<\/mml:mo>\n 0.05<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math><\/jats:alternatives><\/jats:inline-formula>). COX analysis revealed that D-5PS are the independent factors influencing PFS, while MTV is the independent influencing factor of OS.<\/jats:p>\n <\/jats:sec>\n Conclusion<\/jats:title>\n The baseline total MTV obtained by PET\/CT scanning, and D-5PS are crucial prognostic factors in evaluating the prognosis of PTCL-NOS.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s12880-021-00674-5","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T20:05:27Z","timestamp":1633896327000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of pre-treatment and mid-treatment 18F-FDG PET\/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)"],"prefix":"10.1186","volume":"21","author":[{"given":"Yafei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangfa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Tan Su Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huatao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"issue":"3","key":"674_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.beha.2018.07.010","volume":"31","author":"N Khan","year":"2018","unstructured":"Khan N, Ozkaya N, Moskowitz A, Dogan A, Horwitz S. Peripheral t-cell lymphoma: are we making progress? Best Pract Res Clin Haematol. 2018;31(3):306\u201314.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"25","key":"674_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, Cell T. Lymphoma project international. International peripheral t-cell and natural killer\/t-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"9","key":"674_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","volume":"129","author":"A Broccoli","year":"2017","unstructured":"Broccoli A, Zinzani PL. Peripheral t-cell lymphoma, not otherwise specified. Blood. 2017;129(9):1103\u201312.","journal-title":"Blood"},{"issue":"6","key":"674_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.14473","volume":"176","author":"N Schmitz","year":"2017","unstructured":"Schmitz N, de Leval L. How i manage peripheral t-cell lymphoma, not otherwise specified and angioimmunoblastic t-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176(6):851\u201366.","journal-title":"Br J Haematol"},{"issue":"2","key":"674_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.hoc.2016.11.009","volume":"31","author":"M Al-Zahrani","year":"2017","unstructured":"Al-Zahrani M, Savage KJ. Peripheral t-cell lymphoma, not otherwise specified: a review of current disease understanding and therapeutic approaches. Hematol Oncol Clin N Am. 2017;31(2):189\u2013207.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"9","key":"674_CR6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0524","volume":"23","author":"K Laribi","year":"2018","unstructured":"Laribi K, Alani M, Truong C, Baugier de Materre A. Recent advances in the treatment of peripheral t-cell lymphoma. Oncologist. 2018;23(9):1039\u201353.","journal-title":"Oncologist"},{"issue":"3","key":"674_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/hon.2697","volume":"38","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, Rekowski J, Muller SP, Hertenstein B, Franzius C, et al. Baseline and interim pet-based outcome prediction in peripheral t-cell lymphoma: a subgroup analysis of the petal trial. Hematol Oncol. 2020;38(3):244\u201356.","journal-title":"Hematol Oncol"},{"issue":"2","key":"674_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2214\/AJR.09.3665","volume":"195","author":"J Feeney","year":"2010","unstructured":"Feeney J, Horwitz S, Gonen M, Schoder H. Characterization of t-cell lymphomas by fdg pet\/ct. AJR Am J Roentgenol. 2010;195(2):333\u201340.","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"674_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ajh.24128","volume":"90","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Pedersen MB, Hutchings M, Mylam KJ, Madsen J, et al. Utility of interim and end-of-treatment pet\/ct in peripheral t-cell lymphomas: a review of 124 patients. Am J Hematol. 2015;90(11):975\u201380.","journal-title":"Am J Hematol"},{"issue":"4","key":"674_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2967\/jnumed.117.193946","volume":"59","author":"AS Cottereau","year":"2018","unstructured":"Cottereau AS, El-Galaly TC, Becker S, Broussais F, Petersen LJ, et al. Predictive value of pet response combined with baseline metabolic tumor volume in peripheral t-cell lymphoma patients. J Nucl Med. 2018;59(4):589\u201395.","journal-title":"J Nucl Med"},{"issue":"9","key":"674_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/annonc\/mdp030","volume":"20","author":"JYY Ngeow","year":"2009","unstructured":"Ngeow JYY, Quek RHH, Ng DCE, Hee SW, Tao M, et al. High suv uptake on fdg-pet\/ct predicts for an aggressive b-cell lymphoma in a prospective study of primary fdg-pet\/ct staging in lymphoma. Ann Oncol. 2009;20(9):1543\u20137.","journal-title":"Ann Oncol"},{"issue":"10","key":"674_CR12","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","volume":"53","author":"M Meignan","year":"2012","unstructured":"Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, et al. Report on the third international workshop on interim positron emission tomography in lymphoma held in menton, france, 26\u201327 september 2011 and menton 2011 consensus. Leuk Lymphoma. 2012;53(10):1876\u201381.","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"674_CR13","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.7150\/jca.30415","volume":"10","author":"J Xia","year":"2019","unstructured":"Xia J, Zhu HY, Liang JH, Ding CY, Wang L, et al. The prognostic role of 18f-fdg pet\/ct baseline quantitative metabolic parameters in peripheral t-cell lymphoma. J Cancer. 2019;10(23):5805\u201311.","journal-title":"J Cancer"},{"key":"674_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-015-1193-1","volume":"15","author":"SH Jung","year":"2015","unstructured":"Jung SH, Ahn JS, Kim YK, Kweon SS, Min JJ, et al. Prognostic significance of interim pet\/ct based on visual, suv-based, and mtv-based assessment in the treatment of peripheral t-cell lymphoma. BMC Cancer. 2015;15:198.","journal-title":"BMC Cancer"},{"issue":"2","key":"674_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","volume":"3","author":"N Mehta-Shah","year":"2019","unstructured":"Mehta-Shah N, Ito K, Bantilan K, Moskowitz AJ, Sauter C, et al. Baseline and interim functional imaging with pet effectively risk stratifies patients with peripheral t-cell lymphoma. Blood Adv. 2019;3(2):187\u201397.","journal-title":"Blood Adv"},{"issue":"13","key":"674_CR16","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1007\/s00259-018-4093-1","volume":"45","author":"HY Yhim","year":"2018","unstructured":"Yhim HY, Park Y, Han YH, Kim S, Kang SR, et al. A risk stratification model for nodal peripheral t-cell lymphomas based on the nccn-ipi and posttreatment deauville score. Eur J Nucl Med Mol Imaging. 2018;45(13):2274\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"674_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11899-010-0062-x","volume":"5","author":"PP Piccaluga","year":"2010","unstructured":"Piccaluga PP, Agostinelli C, Gazzola A, Mannu C, Bacci F, et al. Prognostic markers in peripheral t-cell lymphoma. Curr Hematol Malig Rep. 2010;5(4):222\u20138.","journal-title":"Curr Hematol Malig Rep"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-021-00674-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-021-00674-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-021-00674-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T20:15:27Z","timestamp":1633896927000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-021-00674-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1186\/s12880-021-00674-5","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave written informed consent before participation in this study.This study was submitted to and approved by Clinical Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"145"}}